BRAF and non-small cell lung carcinoma: Trametinib is a highly selective reversible allosteric inhibitor of MEK1/2 activity, approved in the treatment of cancers with the activation of the RAS/MAPK pathway, such as BRAF V600E mutated metastatic melanoma and BRAF V600E mutated non-small-cell lung cancer [18,19].